Abstract
Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.
| Original language | English |
|---|---|
| Pages (from-to) | 118-119 |
| Number of pages | 2 |
| Journal | Clinical and Experimental Neuroimmunology |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - May 1 2015 |
All Science Journal Classification (ASJC) codes
- Neuroscience (miscellaneous)
- Immunology
- Immunology and Microbiology (miscellaneous)
- Clinical Neurology